Related Experiment Video
Updated: Feb 28, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
18.8K
Neonatal lupus erythematosus
Naoto Yokogawa1, Naofumi Sumitomo2, Masaru Miura2
1Tokyo Metropolitan Tama Medical Center, Department of Rheumatology.
Summary
Maternal anti-SSA antibodies can cause neonatal lupus (NL), a serious condition. Hydroxychloroquine (HCQ) shows promise in reducing cardiac NL risk in future pregnancies for mothers with a history of NL.
Area of Science:
- Immunology
- Pediatrics
- Obstetrics
Background:
- Neonatal lupus (NL) is a passively acquired autoimmune condition linked to maternal anti-SSA antibodies.
- It presents with cardiac and non-cardiac manifestations, including rashes, cytopenia, and liver abnormalities.
- Cardiac NL is a severe complication with high mortality and pacemaker implantation rates.
Purpose of the Study:
- To investigate the risk factors and potential preventative treatments for neonatal lupus.
- To evaluate the efficacy of hydroxychloroquine (HCQ) in reducing the recurrence of cardiac NL.
Main Methods:
- Retrospective analysis of NL registries from American, British, and French studies.
- Ongoing prospective studies in the USA and Japan to confirm findings.
Main Results:
- Maternal anti-SSA antibodies are associated with increased risk of NL in infants.
- Hydroxychloroquine (HCQ) demonstrated a reduced risk of cardiac NL in subsequent pregnancies for mothers with a history of cardiac NL.
Conclusions:
- Early identification of maternal anti-SSA antibodies is crucial for managing NL risks.
- Hydroxychloroquine (HCQ) may be a beneficial intervention for preventing cardiac NL recurrence.
- Establishing international registries is vital for advancing NL research.
